



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم

بسم الله الرحمن الرحيم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكرو فيلم



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكرو فيلم



MONA MAGHRABY



شبكة المعلومات الجامعية
التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY

The Predictive Value of Oral Nicorandil on Contrast Induced Nephropathy in Patients with Renal Insufficiency Undergoing Cardiac Catheterization in Non ST Segment Elevation Acute Coronary Syndrome

A Thesis

*Submitted for Fulfillment of MD Degree
in Cardiology*

Presented By

Ayman Ahmed Mohamed Mohamed Seleim

*Master Degree of Cardiology
Faculty of Medicine, Ain Shams University*

Under Supervision of

Prof. Dr. Osama Mohamed Hassan Abdel-Reheem

*Professor of Cardiology
Faculty of Medicine, Ain Shams University*

Prof. Dr. Ahmed Shawky Abdel-Hameed El-serafy

*Professor of Cardiology
Faculty of Medicine, Ain Shams University*

Dr. Ahmed Ibrahim El-Desoky Khalil

*Lecturer of Cardiology
Faculty of Medicine, Ain Shams University*

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

سَبِّحْ اِنَّكَ لَا تَعْلَمُ لَنَا
اِلَّا مَا عَلَّمْتَنَا اِنَّكَ اَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**, the
Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and
profound gratitude to **Prof. Dr. Osama Mohamed
Hassan Abdel-Reheem**, Professor of Cardiology,
Faculty of Medicine, Ain Shams University, for his keen
guidance, kind supervision, valuable advice and
continuous encouragement, which made the completion
of this work possible.*

*I am also delighted to express my deepest
gratitude and thanks to **Prof. Dr. Ahmed
Shawky Abdel-Hameed El-Serafy**, Professor of
Cardiology, Faculty of Medicine, Ain Shams University,
for his kind care, continuous supervision, valuable
instructions, constant help and great assistance
throughout this work.*

*I am deeply thankful to **Dr. Ahmed Ibrahim
El-Desoky Khalil**, Lecturer of Cardiology, Faculty of
Medicine, Ain Shams University, for his great help,
active participation and guidance.*

*I would like to express my hearty thanks to all my
family for their support till this work was completed.*

*Last but not least my sincere thanks and
appreciation to all patients participated in this study.*

Ayman Ahmed Mohamed Mohamed Seleim

List of Contents

Title	Page No.
List of Tables	i
List of Figures.....	i
List of Abbreviations	vi
Introduction.....	1
Aim of the Work	5
Review of Literature.....	
Chapter (1): Contrast Induced Nephropathy	6
Chapter (2): Nicorandil.....	27
Patients and Methods	33
Results.....	37
Discussion	73
Summary	83
Conclusion	85
Recommendations.....	86
References.....	87

List of Tables

Table No.	Title	Page No.
Table (1):	Factors associated with increased risk of CIN.....	10
Table (2):	Comparison between Nicorandil group and control group as regards age, gender and weight.....	38
Table (3):	Comparison between Nicorandil group and control group as regards smoking status and family history of premature CAD.	41
Table (4):	Comparison between Nicorandil group and control group as regards prior MI, prior angina, prior PCI, prior CABG, type I DM and type II DM.....	42
Table (5):	Comparison between Nicorandil group and control group as regards hypertension, dyslipidemia, PVD, CVS and chest pain onset before admission.	43
Table (6):	Comparison between Nicorandil group and control group as regards systolic arterial blood pressure, diastolic blood pressure, heart rate, peripheral pulsation, cardiac examination, chest auscultation and echocardiography finding.	45
Table (7):	Comparison between Nicorandil group and control group as regards hemoglobin, serum creatinine levels and creatinine clearance measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.....	47
Table (8):	Comparison between Nicorandil group and control group as regards vascular access.	50
Table (9):	Comparison between Nicorandil group and control group as regards vascular lesions, contrast (type and amount), and the incidence of CIN.....	51

List of Tables *(Cont...)*

Table No.	Title	Page No.
Table (10):	Comparison between Nicorandil group and control group as regards contrast (type and amount), and the incidence of CIN.....	52
Table (11):	Comparison between non CIN group and CIN group as regards age, gender and weight.....	54
Table (12):	Comparison between non CIN group and CIN group as regards smoking status, family history of premature CAD and prior MI.....	55
Table (13):	Comparison between non CIN group and CIN group as regards prior angina, prior PCI and prior CABG.....	56
Table (14):	Comparison between non CIN group and CIN group as regards type I DM, type II DM and hypertension.....	57
Table (15):	Comparison between non CIN group and CIN group as regards dyslipidemia, PVD, CVS and chest pain onset before admission.....	58
Table (16):	Comparison between non CIN group and CIN group as regards systolic blood pressure and diastolic blood pressure, heart rate, peripheral pulsation, cardiac examination, chest auscultation and ejection fraction.....	59
Table (17):	Comparison between non CIN group and CIN group as regards hemoglobin, serum creatinine levels and creatinine clearance measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.....	60
Table (18):	Comparison between non CIN group and CIN group as regards vascular access.....	63
Table (19):	Comparison between non CIN group and CIN group as regards vascular lesions.....	64

List of Tables *(Cont...)*

Table No.	Title	Page No.
Table (20):	Comparison between non CIN group and CIN group as regards dye amount and dye type.	65
Table (21):	Comparison among CIN cases between Nicorandil group and control group as regards age, gender and weight.	66
Table (22):	Comparison among CIN cases between Nicorandil group and control group as regards risk factors.	67
Table (23):	Comparison among CIN cases between Nicorandil group and control group as regards systolic blood pressure and diastolic blood pressure, heart rate and ejection fraction.	68
Table (24):	Comparison among CIN cases between Nicorandil group and control group as regards hemoglobin, serum creatinine levels and creatinine clearance measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.	69
Table (25):	Comparison among CIN cases between Nicorandil group and control group as regards vascular access.	70
Table (26):	Comparison among CIN cases between Nicorandil group and control group as regards vascular lesions.	71
Table (27):	Comparison among CIN cases between Nicorandil group and control group as regards contrast (type and amount), and the incidence of CIN.	72

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Scheme of hypothesized pathways contributing to CIN pathogenesis.....	8
Figure (2):	Comparison between CIN risk in diabetics versus non diabetics	11
Figure (3):	Scheme to define CIN risk score	17
Figure (4):	Comparison between control group and Nicorandil group as regards age.....	39
Figure (5):	Comparison between control group and Nicorandil group as regards gender.....	40
Figure (6):	Comparison between control group and Nicorandil group as regards weight.....	40
Figure (7):	Comparison between control group and Nicorandil group as regards smoking status, family history of premature CAD, prior MI, prior angina, prior PCI, prior CABG, type I DM, type II DM, hypertension, dyslipidemia, PVD, CVS and chest pain onset before admission.....	44
Figure (8):	Comparison between control group and Nicorandil group as regards systolic blood pressure and diastolic blood pressure.....	46
Figure (9):	Comparison between control group and Nicorandil group as regards heart rate and ejection fraction.....	46
Figure (10):	Comparison between control group and Nicorandil group as regards serum creatinine levels measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.	49
Figure (11):	Comparison between control group and Nicorandil group as regards creatinine clearance measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.	49

List of Figures *(Cont...)*

Fig. No.	Title	Page No.
Figure (12):	Comparison between control group and Nicorandil group as regards vascular access.	50
Figure (13):	Comparison between control group and Nicorandil group as regards dye amount.....	53
Figure (14):	Comparison between control group and Nicorandil group as regards CIN.....	53
Figure (15):	Comparison between non CIN and CIN groups as regards smoking status, family history of premature CAD and prior MI.	55
Figure (16):	Comparison between non CIN and CIN groups as regards prior angina, prior PCI and prior CABG.	56
Figure (17):	Comparison between non CIN and CIN groups as regards type I DM, type II DM and hypertension.....	57
Figure (18):	Comparison between non CIN and CIN groups as regards dyslipidemia, PVD, CVS and chest pain onset before admission.....	58
Figure (19):	Comparison between non CIN and CIN groups as regards serum creatinine levels measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.....	62
Figure (20):	Comparison between non CIN and CIN groups as regards creatinine clearance measured 24 hours before, 24 hours after the procedure, 72 hours after the procedure and 1 week after the procedure.....	62
Figure (21):	Comparison between non CIN and CIN groups as regards dye amount.	65

List of Abbreviations

Abb.	Full term
<i>ACEIs</i>	<i>Angiotensin converting enzyme inhibitor(s)</i>
<i>ACT</i>	<i>Acetylcysteine for contrast induced nephropathy trial</i>
<i>AKI</i>	<i>Acute kidney injury</i>
<i>BMI</i>	<i>Body mass index</i>
<i>CA</i>	<i>Coronary angiography</i>
<i>CCBs</i>	<i>Calcium channel blocker(s)</i>
<i>CHF</i>	<i>Congestive heart failure</i>
<i>CIN</i>	<i>Contrast induced nephropathy</i>
<i>CKD</i>	<i>Chronic kidney disease</i>
<i>CM</i>	<i>Contrast media</i>
<i>CRRT</i>	<i>Continuous renal replacement therapy</i>
<i>DM</i>	<i>Diabetes mellitus</i>
<i>eGFR</i>	<i>Estimated glomerular filtration rate</i>
<i>HD</i>	<i>Hemodialysis</i>
<i>IABP</i>	<i>Intra-aortic balloon pump</i>
<i>IONA</i>	<i>The impact of Nicorandil in angina</i>
<i>K-ATP</i>	<i>ATP-sensitive potassium</i>
<i>KDIGO</i>	<i>Kidney Disease Improving Global Outcome</i>
<i>LV</i>	<i>Left ventricle</i>
<i>LVEF</i>	<i>Left ventricular ejection fraction</i>
<i>MCE</i>	<i>myocardial contrast echocardiography</i>
<i>mg/dL</i>	<i>Milligrams per deciliter</i>
<i>NAC</i>	<i>N-acetylcysteine</i>
<i>NO</i>	<i>Nitric oxide</i>
<i>NSAIDs</i>	<i>Non-steroidal anti-Inflammatory drugs</i>
<i>NSTEACS</i>	<i>Non ST elevation acute coronary syndrome</i>
<i>NSTEMI</i>	<i>Non ST elevation myocardial infarction</i>
<i>PCI</i>	<i>Percutaneous coronary intervention</i>
<i>PGE1</i>	<i>Prostaglandin E1</i>
<i>RIPC</i>	<i>Remote ischemic preconditioning</i>
<i>RRT</i>	<i>Renal replacement therapy</i>

INTRODUCTION

The diagnosis and management of acute coronary syndromes have progressed significantly. New antithrombotic agents have improved the results of medical treatment. New methods of estimating a patient's risk of an adverse outcome help clinicians to decide who may benefit from invasive treatment that is, coronary angiography (CA) and subsequent revascularization either by percutaneous coronary intervention (PCI) or coronary artery bypass surgery (*Kumar et al., 2009*).

As these therapeutic decisions need to be made soon after admission, the categorization of acute coronary syndromes is now based on the information that is available on admission. If no ST segment elevations are present (normal or depressed ST segments or T wave inversion), a diagnosis of non ST elevation acute coronary syndrome is made (*Peters et al., 2007*).

In clinical studies, contrast induced nephropathy (CIN) is defined as an elevation of serum creatinine level $44.2 \mu\text{mol/l}$ (0.5 mg/dL) or 25% above the baseline within 48–72 hours after contrast administration without an alternative cause (*Chyou et al., 2015*).

CIN can be attributed to intra-renal vasoconstriction, with more frequent incidence in impaired kidneys rather than normal ones. Iodinated contrast media (CM) was considered to

cause CIN by affecting renal blood flow and vascular resistance in impaired kidneys (*Kurihara et al., 2015*).

The risk of CIN rises in chronic kidney disease (CKD) patients, which is defined as an estimated glomerular filtration rate (eGFR) of $< 60 \text{ mL/min/1.73 m}^2$. Certain precautions should be followed before patient's exposure to contrast (*McCullough, 2008*).

Risk stratification scoring systems have been devised to calculate an individual patient's risk of developing CIN. This has mostly been done in patients planned for PCI, especially those with preexisting risk factors. Mehran et al designed a scoring system based on points awarded to each of the following multivariate predictors (*Mehran et al., 2006*):

- Hypotension = 5 points.
- Intra-aortic balloon pump (IABP) use = 5 points.
- CHF = 5 points.
- Serum creatinine $>1.5 \text{ mg/dL}$ = 4 points.
- Age >75 years = 4 points.
- Anemia = 3 points.
- Diabetes mellitus(DM) = 3 points.
- Contrast volume = 1 point for each 100 mL used.